EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving
microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused
by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using
Y-6 sublingual tablet in such study population.